CVS Health on Monday warned that costs of a potent new class of cholesterol treatments and other specialty drugs in development could eclipse those of expensive new medicines and overwhelm the health care system "if rigid cost control mechanisms are not put in place." CVS, the second largest U.S. pharmacy benefit manager which negotiates drug prices for 65 million people through contracts with employers and health plans, noted that two of the new injectable cholesterol fighters - called PCSK9 inhibitors - could be approved by mid-2015 and likely each cost $7,000 to $12,000 a year.